GlassScriptPhysician profile
Chunyang T Wang
NPI 1386890770
$16,050.43
in general payments reported to CMS, 2019-2025
63 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,432 · 2020: $1,441 · 2021: $2,997 · 2022: $1,570 · 2023: $1,939 · 2024: $2,752 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,522 · Education: $87.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,521.99 |
| Education | $87.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,502.79 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Sunovion Pharmaceuticals INC. | $1,441.22 | 2019-2022 | |
| Abbvie INC. | $1,163.14 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Sk Life Science, INC. | $1,121.36 | 2020-2025 | |
| Neurelis, INC. | $1,085.42 | 2020-2025 | Valtoco |
| Lilly USA, LLC | $897.14 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Lundbeck LLC | $581.52 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $411.70 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $401.43 | 2019-2023 | Trokendi Xr, Oxtellar Xr |
| Allergan, INC. | $344.18 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $314.02 | 2022-2025 | |
| Amgen INC. | $313.45 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $301.89 | 2023 | Aptiom |
| Acadia Pharmaceuticals INC | $276.72 | 2019-2025 | Daybue |
| Livanova USA, INC. | $268.84 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
Show all 62 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chunyang Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.